A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B‐cell lymphoma

Summary Bendamustine in combination with rituximab (BR) has been associated with high response rates and acceptable toxicity in older patients with relapsed/refractory diffuse large B‐cell lymphoma (DLBCL). Evaluation of BR is warranted in the front‐line setting for DLBCL patients not eligible for a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2016-10, Vol.175 (2), p.281-289
Hauptverfasser:	Park, Steven I., Grover, Natalie S., Olajide, Oludamilola, Asch, Adam S., Wall, James G., Richards, Kristy L., Sobol, Anna L., Deal, Allison M., Ivanova, Anastasia, Foster, Matthew C., Muss, Hyman B., Shea, Thomas C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Factors Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use bendamustine Bendamustine Hydrochloride - administration & dosage Biomarkers Cause of Death DLBCL elderly patients Female Humans Kaplan-Meier Estimate lymphoma Lymphoma, Large B-Cell, Diffuse - diagnosis Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - mortality Male Neoplasm Staging Prognosis rituximab Rituximab - administration & dosage Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!